These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 15611092)

  • 1. Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins.
    Taniguchi S; Suzuki N; Masuda M; Hisanaga S; Iwatsubo T; Goedert M; Hasegawa M
    J Biol Chem; 2005 Mar; 280(9):7614-23. PubMed ID: 15611092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biochemistry and molecular biology of tauopathies.
    Hasegawa M
    Neuropathology; 2006 Oct; 26(5):484-90. PubMed ID: 17080729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Small molecule inhibitors of alpha-synuclein filament assembly.
    Masuda M; Suzuki N; Taniguchi S; Oikawa T; Nonaka T; Iwatsubo T; Hisanaga S; Goedert M; Hasegawa M
    Biochemistry; 2006 May; 45(19):6085-94. PubMed ID: 16681381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Different inhibitory response of cyanidin and methylene blue for filament formation of tau microtubule-binding domain.
    Hattori M; Sugino E; Minoura K; In Y; Sumida M; Taniguchi T; Tomoo K; Ishida T
    Biochem Biophys Res Commun; 2008 Sep; 374(1):158-63. PubMed ID: 18619417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Taxol-stabilized microtubules promote the formation of filaments from unmodified full-length Tau in vitro.
    Duan AR; Goodson HV
    Mol Biol Cell; 2012 Dec; 23(24):4796-806. PubMed ID: 23087208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High throughput screening for small molecule inhibitors of heparin-induced tau fibril formation.
    Crowe A; Ballatore C; Hyde E; Trojanowski JQ; Lee VM
    Biochem Biophys Res Commun; 2007 Jun; 358(1):1-6. PubMed ID: 17482143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tau mutations in frontotemporal dementia FTDP-17 and their relevance for Alzheimer's disease.
    Goedert M; Spillantini MG
    Biochim Biophys Acta; 2000 Jul; 1502(1):110-21. PubMed ID: 10899436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methylene Blue Inhibits Formation of Tau Fibrils but not of Granular Tau Oligomers: A Plausible Key to Understanding Failure of a Clinical Trial for Alzheimer's Disease.
    Soeda Y; Saito M; Maeda S; Ishida K; Nakamura A; Kojima S; Takashima A
    J Alzheimers Dis; 2019; 68(4):1677-1686. PubMed ID: 30909223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cysteine-Independent Inhibition of Alzheimer's Disease-like Paired Helical Filament Assembly by Leuco-Methylthioninium (LMT).
    Al-Hilaly YK; Pollack SJ; Rickard JE; Simpson M; Raulin AC; Baddeley T; Schellenberger P; Storey JMD; Harrington CR; Wischik CM; Serpell LC
    J Mol Biol; 2018 Oct; 430(21):4119-4131. PubMed ID: 30121297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aggregation Kinetics and Filament Structure of a Tau Fragment Are Influenced by the Sulfation Pattern of the Cofactor Heparin.
    Townsend D; Fullwood NJ; Yates EA; Middleton DA
    Biochemistry; 2020 Oct; 59(41):4003-4014. PubMed ID: 32954725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative characterization of heparin binding to Tau protein: implication for inducer-mediated Tau filament formation.
    Zhu HL; Fernández C; Fan JB; Shewmaker F; Chen J; Minton AP; Liang Y
    J Biol Chem; 2010 Feb; 285(6):3592-3599. PubMed ID: 19959468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Age-dependent induction of congophilic neurofibrillary tau inclusions in tau transgenic mice.
    Ishihara T; Zhang B; Higuchi M; Yoshiyama Y; Trojanowski JQ; Lee VM
    Am J Pathol; 2001 Feb; 158(2):555-62. PubMed ID: 11159192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tau in paired helical filaments is functionally distinct from fetal tau: assembly incompetence of paired helical filament-tau.
    Yoshida H; Ihara Y
    J Neurochem; 1993 Sep; 61(3):1183-6. PubMed ID: 8360683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tau pathology in Alzheimer disease and other tauopathies.
    Iqbal K; Alonso Adel C; Chen S; Chohan MO; El-Akkad E; Gong CX; Khatoon S; Li B; Liu F; Rahman A; Tanimukai H; Grundke-Iqbal I
    Biochim Biophys Acta; 2005 Jan; 1739(2-3):198-210. PubMed ID: 15615638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Azure C Targets and Modulates Toxic Tau Oligomers.
    Lo Cascio F; Kayed R
    ACS Chem Neurosci; 2018 Jun; 9(6):1317-1326. PubMed ID: 29378132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tau Fibril Formation in Cultured Cells Compatible with a Mouse Model of Tauopathy.
    Matsumoto G; Matsumoto K; Kimura T; Suhara T; Higuchi M; Sahara N; Mori N
    Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29772786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of tau fibrillization in vitro.
    Xu S; Brunden KR; Trojanowski JQ; Lee VM
    Alzheimers Dement; 2010 Mar; 6(2):110-7. PubMed ID: 20298971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Study of the green tea polyphenols catechin-3-gallate (CG) and epicatechin-3-gallate (ECG) as proteasome inhibitors.
    Wan SB; Chen D; Dou QP; Chan TH
    Bioorg Med Chem; 2004 Jul; 12(13):3521-7. PubMed ID: 15186836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tau proteins and neurofibrillary degeneration.
    Goedert M; Spillantini MG; Crowther RA
    Brain Pathol; 1991 Jul; 1(4):279-86. PubMed ID: 1669718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disaggregation of tau as a therapeutic approach to tauopathies.
    Duff K; Kuret J; Congdon EE
    Curr Alzheimer Res; 2010 May; 7(3):235-40. PubMed ID: 20088807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.